Ken Griffin Bio Cardia, Inc. Transaction History

Citadel Advisors LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.37 - $1.07 $12,442 - $35,983	33,629 New	33,629 $22,000
Q2 2023 Aug 14, 2023	SELL	$1.52 - $2.8 $15,715 - $28,949	-10,339 Reduced 46.61%	11,844 $31,000
Q1 2023 May 15, 2023	BUY	$1.87 - $2.54 $19,833 - $26,939	10,606 Added 91.61%	22,183 $43,000
Q4 2022 Feb 14, 2023	BUY	$1.61 - $32.1 $18,638 - $371,621	11,577 New	11,577 $24,000
Q2 2022 Aug 15, 2022	SELL	$17.7 - $32.55 $460,554 - $846,950	-26,020 Reduced 59.55%	17,675 $26,000
Q1 2022 May 16, 2022	SELL	$21.3 - $39.0 $176,385 - $322,959	-8,281 Reduced 15.93%	43,695 $90,000
Q4 2021 Feb 14, 2022	BUY	$25.65 - $46.05 $838,549 - $1.51 Million	32,692 Added 169.53%	51,976 $0
Q3 2021 Nov 15, 2021	SELL	$42.6 - $58.65 $514,991 - $709,019	-12,089 Reduced 38.53%	19,284 $61,000
Q2 2021 Aug 16, 2021	BUY	$48.9 - $74.85 $480,491 - $735,476	9,826 Added 45.6%	31,373 $0
Q1 2021 May 17, 2021	BUY	$51.3 - $78.15 $254,550 - $387,780	4,962 Added 29.92%	21,547 $94,000
Q4 2020 Feb 16, 2021	BUY	$28.8 - $100.5 $477,648 - $1.67 Million	16,585 New	16,585 $57,000

Ticker BCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,758,200
Market Cap $41.2M
Description
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary di...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.